Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.6 BRL | +5.26% | +8.49% | -52.18% |
03-28 | Transcript : Diagnósticos da América S.A., Q4 2023 Earnings Call, Mar 28, 2024 | |
03-27 | Diagnósticos da América S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-52.18% | 670M | C+ | ||
-14.92% | 84.68B | B- | ||
+13.30% | 81.12B | C+ | ||
+10.92% | 29.4B | C+ | ||
-12.71% | 16.73B | B | ||
-3.06% | 16.36B | A- | ||
-2.63% | 14.92B | A- | ||
-3.97% | 11.66B | A- | ||
-1.42% | 11.72B | A- | ||
-31.75% | 11.77B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DASA3 Stock
- Ratings Diagnosticos da América S.A.